|
Molecular properties generated using the CDK |
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes (source: FDA (2013)) |
IUPAC Name ![]() |
| 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 8814 | alogliptin |
Synonyms ![]() |
| Nesina® |
| SYR-322 |
| Vipidia® |
Database Links ![]() |
|
| CAS Registry No. | 850649-61-5 (source: Scifinder) |
| ChEMBL Ligand | CHEMBL376359 |
| DrugBank Ligand | DB06203 |
| PubChem CID | 11450633 |
| RCSB PDB Ligand | T22 |
| Search Google for chemical match using the InChIKey | ZSBOMTDTBDDKMP-OAHLLOKOSA-N |
| Search Google for chemicals with the same backbone | ZSBOMTDTBDDKMP |
| Search PubMed clinical trials | alogliptin |
| Search PubMed titles | alogliptin |
| Search PubMed titles/abstracts | alogliptin |
| Wikipedia | Alogliptin |
| Comments |
| Alogliptin is a once-daily, oral dipeptidyl peptidase-4 (DPP-4) inhibitor class anti-diabetic drug. |